NCT01785186 - Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design | Biotech Hunter

Enrollment

365

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

March 31, 2015

Conditions

Tuberculosis, Pulmonary

Interventions

DRUG

SQ109

SQ109 300 mg

DRUG

Rifampicin

Rifampicin 10 to 35 mg/kg

DRUG

Moxifloxacin

Moxifloxacin 400mg

DRUG

isoniazid

isoniazid 75 mg

DRUG

pyrazinamide

pyrazinamide 400 mg

DRUG

ethambutol

ethambutol 275 mg

DIETARY_SUPPLEMENT

pyridoxine

pyridoxine 25 mg

Trial Locations (7)

2092

Wits Health Consortium, Johannesburg

2193

The Aurum Institute for Health Research, Johannesburg

2236

Kilimanjaro Christian Medical Centre (KCMC) / Kilimanjaro Clinical Research Institute (KCRI) (with affiliated field sites such as Kibong'oto National Tuberculosis Hospital Same, Mererani, Chekereni and Mawenzi Regional Hospital), Moshi

7530

TASK Applied Science, Bellville

7700

University of Cape Town, Centre for Tuberculosis Research Innovation, Cape Town

P.O.Box 74

Ifakara Health Institute, Bagamoyo

P.O. Box 2410

NIMR - Mbeya Medical Research Programme, Mbeya